Ceftiofur (Naxcel / Excenel)

Ceftiofur, marketed under the veterinary brand names Naxcel and Excenel among others, is a third-generation cephalosporin antibiotic specifically developed and FDA-approved for veterinary use, making it one of the most widely utilized antibiotics in equine medicine. As a beta-lactam antibiotic with broad-spectrum activity against both gram-positive and gram-negative bacteria, ceftiofur provides reliable coverage against many of the pathogens most commonly responsible for equine bacterial infections. The FDA approval for use in horses, along with established pharmacokinetic data and a favorable safety profile, has made ceftiofur a first-line antibiotic choice for many equine practitioners managing respiratory infections, wound infections, and other bacterial diseases.

The mechanism of action of ceftiofur follows the characteristic beta-lactam pattern of inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins essential for peptidoglycan cross-linking and cell wall structural integrity. Ceftiofur achieves bactericidal effects by disrupting cell wall synthesis in actively dividing bacteria, leading to osmotic instability, cell lysis, and bacterial death. The molecular structure of ceftiofur provides enhanced stability against many bacterial beta-lactamase enzymes compared to earlier generation cephalosporins, contributing to its activity against a broad spectrum of equine pathogens. Ceftiofur is rapidly metabolized to desfuroylceftiofur, an active metabolite that retains antibacterial activity and contributes significantly to the overall therapeutic effect.

Ceftiofur is available in two primary formulations for equine use with distinct pharmacokinetic properties. Ceftiofur sodium (Naxcel) requires daily or more frequent administration due to its relatively short half-life and is suitable for intravenous or intramuscular injection. Ceftiofur crystalline free acid (Excenel RTU) provides extended duration of action through slow release from the injection site, allowing less frequent dosing with protocols calling for administration every 72 to 96 hours for certain indications. The choice between formulations depends on the clinical situation, administration frequency preferences, and individual patient factors that the prescribing veterinarian weighs in treatment planning.

The safety profile of ceftiofur in horses is well-characterized given its FDA-approved status and extensive clinical use over many years. Adverse effects are relatively uncommon when the medication is used according to label directions, though as with all antibiotics, the potential for adverse reactions exists. Injection site reactions are the most commonly reported adverse effect, particularly with the crystalline free acid formulation. Veterinary supervision ensures appropriate patient selection, proper dosing based on formulation and indication, and monitoring for adverse effects throughout the treatment course. The established track record of ceftiofur provides practitioners and horse owners confidence in its efficacy and safety profile.

The primary FDA-approved indication for ceftiofur in horses is the treatment of respiratory infections caused by susceptible strains of Streptococcus zooepidemicus, making it a first-line choice for bacterial respiratory disease in equine patients. Lower respiratory tract infections including bacterial pneumonia and pleuropneumonia commonly involve S. zooepidemicus and other streptococcal species that respond well to ceftiofur therapy. The drug's proven efficacy against these common respiratory pathogens, combined with its favorable safety profile and FDA-approved status, has established ceftiofur as a cornerstone of respiratory disease management in horses.

Strangles, caused by Streptococcus equi subspecies equi, represents one of the most common and economically significant infectious diseases affecting horses worldwide. Ceftiofur demonstrates excellent activity against S. equi and is frequently employed in the treatment of strangles, particularly in cases involving systemic illness, complications such as bastard strangles, or situations where aggressive treatment is warranted. The decision to treat strangles with antibiotics versus allowing natural abscess maturation and drainage involves clinical judgment, as antibiotic therapy may in some cases interfere with the development of protective immunity. Ceftiofur's activity against the causative organism makes it an effective choice when antibiotic treatment of strangles is indicated.

Metritis and other reproductive tract infections in mares respond to ceftiofur therapy when caused by susceptible bacteria. Post-breeding endometritis, post-partum metritis, and other uterine infections commonly involve gram-negative and gram-positive organisms within ceftiofur's spectrum of activity. The drug achieves therapeutic concentrations in reproductive tract tissues, supporting its use for these infections. Breeding farm practitioners frequently utilize ceftiofur as part of their management protocols for mares with uterine infections, often in conjunction with uterine lavage and other therapeutic measures.

Skin and soft tissue infections including wound infections, cellulitis, and abscess formation may be treated with ceftiofur when caused by susceptible organisms. Traumatic wounds contaminated with mixed bacterial flora often contain organisms responsive to ceftiofur's broad-spectrum coverage. Surgical site infections, injection site complications, and other soft tissue infections in horses represent additional applications for ceftiofur therapy. The favorable tissue penetration of ceftiofur supports its efficacy for infections involving skin, subcutaneous tissue, and muscle.

Orthopedic infections including septic arthritis and osteomyelitis may warrant ceftiofur therapy, particularly when culture results indicate susceptibility of the causative organism. The serious nature of bone and joint infections typically requires prolonged antibiotic courses, and ceftiofur's FDA-approved status and established safety profile support its use for these extended treatments. Regional limb perfusion techniques can deliver high local concentrations of ceftiofur sodium directly to infected tissues in the distal limb, potentially improving outcomes for localized orthopedic infections.

Dosing of ceftiofur in horses depends critically on which formulation is being used, as ceftiofur sodium and ceftiofur crystalline free acid have distinct pharmacokinetic properties requiring different dosing protocols. Veterinary determination of the appropriate formulation and dosing regimen considers the type and severity of infection, desired administration frequency, individual patient factors, and practical management considerations. Accurate body weight measurement is essential regardless of formulation, as ceftiofur doses are calculated on a milligram-per-kilogram basis with different dosing parameters for each formulation.

Ceftiofur sodium (Naxcel) is typically dosed at 2.2 to 4.4 milligrams per kilogram of body weight, administered intramuscularly or intravenously once or twice daily depending on the indication and severity of infection. The intravenous route provides rapid achievement of therapeutic blood and tissue concentrations for serious infections, while intramuscular administration is appropriate for most routine applications. The relatively short half-life of ceftiofur sodium necessitates daily or twice-daily dosing to maintain adequate drug concentrations throughout the treatment period. Higher doses within the approved range may be employed for serious infections or organisms with higher minimum inhibitory concentrations.

Ceftiofur crystalline free acid (Excenel RTU) employs a different dosing paradigm, with the label dose of 6.6 milligrams per kilogram administered intramuscularly providing sustained drug release over an extended period. This extended-release formulation is typically administered at intervals of 72 to 96 hours depending on the indication, dramatically reducing the frequency of injections compared to ceftiofur sodium. The crystalline free acid formulation is administered only intramuscularly, as the suspension characteristics are not suitable for intravenous use. The neck is the approved injection site for the crystalline free acid formulation in horses.

The choice between ceftiofur formulations involves weighing several factors. Ceftiofur sodium offers more flexible dosing with the ability to adjust frequency based on infection severity and the option for intravenous administration when rapid drug delivery is desired. Ceftiofur crystalline free acid offers convenience through reduced injection frequency, which may improve compliance and reduce stress from repeated injections. For hospitalized patients where daily medication administration is routine, ceftiofur sodium may be preferred. For ambulatory patients or situations where reduced handling is beneficial, the extended-release crystalline free acid formulation may be advantageous.

Treatment duration with ceftiofur varies based on the type and severity of infection being treated. Respiratory infections typically require treatment courses of three to five days or longer, continuing until clinical signs resolve. Soft tissue infections may require similar or longer treatment durations depending on severity and response. Orthopedic infections and other deep-seated infections typically require extended treatment courses lasting several weeks. Premature discontinuation of antibiotic therapy risks treatment failure and development of resistant bacteria, making completion of the full prescribed course essential.

If a dose of ceftiofur is missed during a treatment course, the missed dose should be administered as soon as recognized unless the next scheduled dose is imminent. For ceftiofur sodium given daily, a delay of several hours is generally acceptable, but doubling doses is not recommended. For ceftiofur crystalline free acid given every 72-96 hours, the extended dosing interval provides more flexibility, but significantly delayed doses may result in subtherapeutic drug levels between administrations. Maintaining consistent dosing maximizes treatment efficacy.

Ceftiofur is generally well-tolerated by horses when administered according to label directions, with adverse effects being relatively uncommon in clinical practice. The FDA-approved status of ceftiofur means that its safety profile has been evaluated through formal approval studies and confirmed by extensive post-marketing experience. Despite this favorable overall profile, awareness of potential adverse effects allows appropriate monitoring and early intervention should problems develop during treatment.

Injection site reactions represent the most commonly reported adverse effects with ceftiofur, particularly with the crystalline free acid formulation (Excenel RTU). Horses may develop swelling, firmness, or discomfort at intramuscular injection sites following ceftiofur administration. The crystalline free acid formulation is specifically associated with injection site reactions that may persist for several days due to the depot effect of this slow-release formulation. Label directions specify neck injection for the crystalline free acid formulation, and owners should be advised that visible swelling at injection sites is relatively common but typically resolves without specific treatment.

Gastrointestinal disturbances are possible with ceftiofur as with other broad-spectrum antibiotics that can affect the normal intestinal microflora. Horses receiving ceftiofur may develop soft stools or mild diarrhea, particularly with prolonged treatment courses. While ceftiofur appears to have relatively lower risk of causing antibiotic-associated diarrhea compared to some other antibiotics, the potential exists and warrants monitoring. Any horse developing significant diarrhea, watery stool, abdominal pain, or signs of colic during ceftiofur therapy requires prompt veterinary evaluation to assess for serious intestinal complications.

Hypersensitivity reactions to ceftiofur are uncommon but represent potentially serious adverse effects. Allergic reactions can manifest as urticaria, facial swelling, pruritus, or more severe systemic reactions including anaphylaxis with cardiovascular compromise and respiratory distress. Horses with known allergies to cephalosporins or penicillins should not receive ceftiofur due to potential cross-reactivity. Any horse showing signs of allergic reaction during or after ceftiofur administration requires immediate veterinary attention and discontinuation of the medication.

Other adverse effects reported with ceftiofur include rare instances of bleeding or coagulation abnormalities, though these are uncommon with typical treatment protocols. The label for ceftiofur crystalline free acid notes that some horses may exhibit transient agitation during or immediately following injection, which typically resolves quickly. Any unexpected clinical signs, deterioration, or failure to respond appropriately during ceftiofur therapy should prompt veterinary reassessment to determine whether findings represent adverse drug effects, progression of the underlying infection, or concurrent disease processes.

Documented hypersensitivity to cephalosporin antibiotics represents the primary absolute contraindication for ceftiofur use in horses. Horses with known allergies to ceftiofur or other cephalosporins should not receive this medication due to the risk of potentially serious allergic reactions upon re-exposure. Complete medication history review before initiating ceftiofur therapy helps identify horses with known cephalosporin allergies, allowing selection of alternative antibiotics from non-cross-reacting drug classes. Previous allergic reactions of any severity, from mild urticaria to severe anaphylaxis, indicate that ceftiofur should be avoided.

Cross-reactivity between cephalosporins and penicillins requires careful consideration when selecting antibiotics for horses with documented or suspected penicillin allergies. The structural similarities between these beta-lactam antibiotic classes mean that horses with penicillin allergies may experience allergic reactions to cephalosporins including ceftiofur. While actual cross-reactivity rates may be lower than historically believed, the potential severity of anaphylactic reactions supports avoiding cephalosporins in horses with confirmed penicillin allergies unless no suitable alternatives exist. Alternative antibiotic classes should be considered for horses with documented beta-lactam hypersensitivity.

Specific formulation considerations create relative contraindications for certain administration routes. Ceftiofur crystalline free acid (Excenel RTU) is formulated specifically for intramuscular injection and should not be administered intravenously due to its suspension characteristics. The label specifies neck injection for the crystalline free acid formulation, and deviation from this injection site may increase the risk of adverse reactions or alter drug release kinetics. Ceftiofur sodium can be administered either intramuscularly or intravenously, providing more flexibility when different routes are indicated.

Horses intended for human consumption should not receive ceftiofur or must observe extended withdrawal periods if treated, as residues in edible tissues raise food safety concerns. While most horses in the United States are not destined for slaughter, awareness of this consideration is relevant for some equine populations. The crystalline free acid formulation label specifically prohibits use in horses intended for human consumption. Additionally, the combination of ceftiofur with certain other medications may require caution based on potential drug interactions, as discussed in the Drug Interactions section.

Ceftiofur exhibits several drug interactions that warrant consideration when developing comprehensive treatment protocols for equine patients. The combination of ceftiofur with aminoglycoside antibiotics represents both a potential therapeutic synergy and a concern for increased nephrotoxicity. When ceftiofur and aminoglycosides such as gentamicin or amikacin are administered together, they may provide synergistic bactericidal activity against certain pathogens, potentially improving outcomes for serious infections. However, the combination also increases the potential for kidney damage, necessitating careful renal function monitoring and maintenance of adequate hydration throughout concurrent treatment.

Interactions with other potentially nephrotoxic medications extend beyond aminoglycosides to include non-steroidal anti-inflammatory drugs commonly used in equine practice. While ceftiofur alone has minimal nephrotoxic potential, concurrent administration with phenylbutazone, flunixin meglumine, or other NSAIDs may contribute to renal stress in susceptible patients. Horses that are dehydrated, have pre-existing renal compromise, or are receiving multiple potentially nephrotoxic agents warrant more careful monitoring when ceftiofur is part of their treatment regimen. Ensuring adequate hydration helps protect kidney function during concurrent therapy.

Bacteriostatic antibiotics including tetracyclines and chloramphenicol may theoretically interfere with the bactericidal action of ceftiofur by inhibiting bacterial cell division that beta-lactam antibiotics depend upon for their killing mechanism. While the clinical significance of this potential antagonism is debated and may vary by organism and infection site, combining bactericidal and bacteriostatic antibiotics is generally avoided when possible. When culture and sensitivity results indicate susceptibility to multiple antibiotic classes, selecting agents with complementary mechanisms rather than potentially antagonistic ones may optimize treatment outcomes.

Probenecid, though rarely used in equine medicine, can inhibit the renal tubular secretion of ceftiofur, resulting in higher and more prolonged blood concentrations. This pharmacokinetic interaction could theoretically be exploited therapeutically but also increases the potential for concentration-related adverse effects. Awareness of this interaction is relevant when reviewing comprehensive medication lists of horses referred from other facilities. Veterinary guidance helps navigate antibiotic selection and monitoring requirements when multiple medications are being administered concurrently.

Monitoring requirements during ceftiofur therapy focus on clinical response to treatment and surveillance for adverse effects, with intensity of monitoring proportional to illness severity and patient risk factors. Horses with serious infections requiring hospitalization should be assessed regularly for improvement in clinical parameters including temperature, respiratory rate and effort, appetite, and specific signs related to the infection being treated. Injection site monitoring is advisable, particularly with the crystalline free acid formulation, to detect excessive reactions that might require attention. For routine outpatient treatment, owners should observe their horse daily for overall improvement and report any concerns promptly.

Special populations of horses require additional consideration when ceftiofur therapy is planned. Neonatal foals may receive ceftiofur as part of septicemia treatment protocols, often in combination with aminoglycosides for broader coverage. The combination requires attention to hydration status and renal function monitoring given the nephrotoxic potential of aminoglycosides. Pregnant and lactating mares have received ceftiofur without documented fetal or neonatal adverse effects, but as with all medications during these life stages, use should be based on clear clinical indication. Geriatric horses with diminished organ function may require consideration of potential effects on drug elimination.

Competition and performance horses face significant concerns regarding ceftiofur use due to its regulatory status as a prohibited substance during competition. FEI, USEF, state racing commissions, and breed organization rules prohibit the presence of antibiotics including ceftiofur during competition. Withdrawal times for ceftiofur vary depending on the formulation used, with the crystalline free acid formulation having extended detection times due to its depot release characteristics. Conservative withdrawal periods should be observed before competition, and consultation with a veterinarian familiar with current regulations is essential. Detailed medication records should document formulation, dose, route, and dates of administration for any performance horse receiving ceftiofur.

Injection site selection and technique affect both drug delivery and the likelihood of local reactions. For ceftiofur sodium, large muscle masses such as the semimembranosus/semitendinosus muscles or the neck muscles are appropriate injection sites, with rotation recommended for multi-day treatment courses. For ceftiofur crystalline free acid, the label specifies the neck as the injection site, and adherence to this specification is important for both efficacy and safety. Proper aseptic technique during injection prevents introduction of bacteria that could cause injection site infections.

Long-term considerations for ceftiofur use relate to antimicrobial stewardship and the importance of preserving antibiotic effectiveness. As a critically important antimicrobial, ceftiofur should be used judiciously and preferably based on culture and sensitivity results when practical. Completing prescribed treatment courses while avoiding unnecessarily prolonged therapy supports both treatment success and resistance prevention. When culture results indicate susceptibility to narrower-spectrum antibiotics, de-escalation from ceftiofur may be appropriate to preserve this broad-spectrum agent for cases truly requiring its coverage profile.

Proper storage of ceftiofur products maintains medication potency and safety throughout the product's shelf life. Ceftiofur sodium (Naxcel) in powder form should be stored at controlled room temperature protected from light. After reconstitution, ceftiofur sodium solutions have limited stability and should be refrigerated if not used immediately, with specific storage duration and conditions following manufacturer guidelines. Pre-mixed solutions should be inspected visually before each use, and any solution showing particulate matter, cloudiness, or color change should be discarded.

Ceftiofur crystalline free acid (Excenel RTU) comes as a ready-to-use suspension requiring no reconstitution, simplifying preparation but necessitating proper storage to maintain suspension characteristics and drug potency. This formulation should be stored at controlled room temperature and protected from freezing, which can damage the suspension. The vial should be shaken well before each use to ensure uniform distribution of the crystalline drug throughout the suspension vehicle. Multi-dose vial practices should follow appropriate guidelines for preventing contamination between uses.

Safe handling of ceftiofur protects personnel from potential adverse effects of drug exposure. Individuals with known allergies to cephalosporins or penicillins should avoid handling ceftiofur products due to the potential for allergic reactions from skin contact or accidental injection. Wearing gloves during medication preparation and administration provides a barrier against dermal exposure. Accidental self-injection, while rare, requires immediate medical attention, particularly for individuals with beta-lactam allergies. Standard precautions for handling injectable medications, including proper needle handling and disposal, should be observed.

Disposal of unused or expired ceftiofur should follow appropriate guidelines for pharmaceutical waste. Antibiotics should not be disposed of in regular trash or flushed into wastewater systems, as environmental release contributes to antimicrobial resistance in environmental bacteria. Many veterinary clinics offer pharmaceutical disposal services, and take-back programs may be available in some areas. Used needles and syringes should be placed in appropriate sharps containers for proper disposal according to local regulations. Maintaining inventory control to minimize waste and ensuring use of medication before expiration supports both cost-effective practice and environmental responsibility.

Draft horses requiring ceftiofur therapy present practical considerations related to their substantial body mass, with weights commonly ranging from 1,600 to 2,200 pounds or more requiring correspondingly larger medication volumes to achieve therapeutic doses. For ceftiofur sodium, the volume of reconstituted solution needed for draft horse doses may necessitate consideration of injection site capacity and potential division across multiple sites. For ceftiofur crystalline free acid, the label dose based on body weight results in substantial injection volumes that require attention to proper injection technique. Despite their size, draft horses are not known to have significantly different ceftiofur pharmacokinetics compared to light horse breeds.

Light horses and warmbloods representing the majority of sport and pleasure horses typically fall within standard dosing parameters for ceftiofur therapy. These breeds ranging from approximately 900 to 1,400 pounds generally tolerate ceftiofur well with routine injection volumes. Performance horse considerations are particularly relevant for these populations, with competition regulations and withdrawal times requiring careful attention for any horse potentially returning to competition after treatment. Both FEI-level warmbloods and breed show horses must observe appropriate drug-free periods, with the crystalline free acid formulation requiring extended withdrawal times due to its depot release characteristics.

Ponies and miniature horses require careful attention to dosing precision due to their smaller body mass. Accurate weight measurement using appropriately sized weight tapes or scales ensures proper dose calculation. The relatively smaller injection volumes required for ponies and miniatures may allow use of smaller gauge needles, potentially reducing injection site discomfort. The metabolic characteristics of ponies, including their tendency toward insulin dysregulation, do not directly affect ceftiofur pharmacology but may indicate concurrent health considerations relevant to overall case management.

Breed-specific genetic conditions may influence treatment considerations without directly affecting ceftiofur metabolism. Quarter Horses and related breeds with genetic conditions such as HYPP, PSSM, or MH may have concurrent management needs during treatment of bacterial infections. Arabian horses affected by SCID have profoundly compromised immune function affecting their ability to fight infection regardless of antibiotic selection. Friesians with predispositions to certain health conditions may require consideration of these factors in comprehensive treatment planning. Individual breed characteristics and genetic backgrounds should be considered as part of overall patient assessment when treating infections requiring ceftiofur.

Within the cephalosporin antibiotic class, ceftiofur occupies a central position as the only FDA-approved third-generation cephalosporin for equine use, but several alternatives exist for different clinical situations. First-generation cephalosporins such as cefazolin provide primarily gram-positive coverage and are commonly used for surgical prophylaxis and infections with confirmed susceptible organisms. Other third-generation cephalosporins including cefotaxime offer similar spectrum coverage and are used off-label for certain equine infections, particularly in neonatal foals. Fourth-generation cephalosporins such as cefepime provide broader coverage including enhanced Pseudomonas activity for resistant infections. Selection among cephalosporin options should be based on culture results, FDA approval status considerations, and specific clinical requirements.

When cephalosporins are contraindicated or when different antimicrobial mechanisms are desired, alternative antibiotic classes offer treatment options for equine bacterial infections. Penicillins including procaine penicillin G and potassium penicillin share beta-lactam mechanism and have overlapping spectrum for many equine pathogens, though cross-reactivity concerns apply for horses with cephalosporin allergies. Aminoglycosides provide gram-negative coverage through a different mechanism and are often combined with beta-lactams for serious infections. Trimethoprim-sulfamethoxazole combinations offer broad coverage through folate synthesis inhibition. Fluoroquinolones such as enrofloxacin provide broad-spectrum activity but carry considerations including cartilage effects in young horses.

Complementary therapies and supportive care measures often accompany ceftiofur treatment to optimize outcomes. For respiratory infections, environmental management including dust reduction and ventilation improvement supports recovery. For wound infections, appropriate wound care including debridement, lavage, and bandaging complements antibiotic therapy. Anti-inflammatory medications may be indicated for fever and pain management, with appropriate awareness of potential drug interactions discussed earlier. Nutritional support and general husbandry ensure that horses have optimal conditions for recovery from bacterial infections. Veterinary guidance coordinates antibiotic selection, complementary therapies, and monitoring to achieve the best possible outcomes for horses requiring antimicrobial treatment.